Chemotherapy-induced peripheral neuropathy
Conditions
Interventions
Tumor Group (Received >>= 4 cycles of neurotoxic chemotherapy regimen (paclitaxel and oxaliplatin)):None
Control Group (50 healthy volunteers and 50 orthopedic surgery patients):None
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Age 18–75 years Patients with pathologically confirmed solid tumors (lung cancer, gastric cancer, breast cancer, colorectal cancer, cervical cancer, endometrial cancer) Scheduled to receive >= 4 cycles of neurotoxic chemotherapy regimen (paclitaxel and oxaliplatin) ECOG performance status <=2 No severe hepatic or renal impairment.
Exclusion criteria
Exclusion criteria: Peripheral neuropathy caused by diabetes, HIV infection, or other causes; Previous treatment with neurotoxic medications; Inability to complete follow-up or refusal to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NCI-CTCAE ; | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS Score;EORTC QLQ-CIPN20;Neurophysiological Testing; | — |
Countries
China
Contacts
Public ContactHuidan Lin
The First Affiliated Hospital of Ningbo University
Outcome results
None listed